Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: The role of quetiapine XR in the treatment of unipolar and bipolar depression

Rivista di Psichiatria

Volumn 47, Issue 6, 2012, Pages 489-497

  Pompili, Maurizio ^a,b   Rihmer, Zoltan ^c   Gonda, Xenia ^c   Serafini, Gianluca ^a   Sher, Leo ^d   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MCLEAN HOSPITAL   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Insomnia; Major depression; Quetiapine; Side effects; Suicide

Indexed keywords

AGOMELATINE; ARIPIPRAZOLE; DULOXETINE; FLUOXETINE; LITHIUM; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR I DISORDER; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; ONSET AGE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DIBENZOTHIAZEPINES; HUMANS; RISK FACTORS; SLEEP; SUICIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871544836     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: 10.1708/1183.13092     Document Type: Review

References (81)

1. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999; 156: 181-9. (Pubitemid 29077107)
2. Pompili M, Innamorati M, Szanto K, et al. Life events as precipitants of suicide attempts among first-time suicide attempters, repeaters, and non-attempters. Psychiatry Res 2011; 186: 300-5.
3. Shneidman ES. Suicide as psychache. J Nerv Ment Dis 1993; 181: 145-7. (Pubitemid 23090169)
4. Pompili M. Exploring the phenomenology of suicide. Suicide Life Threat Behav 2010; 40: 234-44.
5. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012; 21: 1503-22.
6. Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012; 17: 105-26.
7. Mancini M, Gianni W, Rossi A, Amore M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opin Pharmacother 2009; 10: 847-60.
8. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011; 31: 180-6.
9. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001; 62 (suppl 16): 18-25.
10. Jefferson JW. Strategies for switching antidepressants to achieve maximum efficacy. J Clin Psychiatry 2008; 69 (suppl E1): 14-8.
11. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus accross-class switches. Biol Psychiatry 2008; 63: 699-704. (Pubitemid 351329277)
12. Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 2007; 20: 17-22. (Pubitemid 44901071)
13. Altamura AC, Dell'Osso B, Vismara S, Mundo E. May duration of untreated illness influence the long-term cousre of major depressive disorder? Eur Psychiatry 2008; 23: 92-6.
14. Henkel V, Seemüller F, Obermeier M, et al. Does early improvmenet triggered by antidepressants predict response/remission? Analyis of data from a naturalsitic study on a large sample of inaptients with major depression. J Affect Disord 2009; 115: 439-49.
15. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41-7.
16. Goodwin FK, Jamison KR. Manic-depressive illness. Bipolar disorders and recurrent depression. 2nd edition. New York: Oxford University Press, 2007.
17. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behavior. JAMA 2004; 292: 338-48.
18. Rihmer Z, Aksikal HS. Do antidepressants t(h)reat(en) depressives? Toward a judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide rates from many countries. J Affect Disord 2006; 94: 3-13. (Pubitemid 44093033)
19. Fawcet J, Scheftner WA, Fogg L. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990; 147: 1189-94. (Pubitemid 20275373)
20. Paffenbarger RS, Lee IM, Leung R. Physical activity and personal characteristics associated with depression and suicide in American college men. Acta Psychiatr Scand 1994; 337S: 16-22. (Pubitemid 24147799)
21. Taylor DJ, Lichstein KL, Durrence HH. Insomnia as a health risk factor. Behav Sleep Med 2003; 1: 227-47.
22. McGirr A, Renaud J, Seguin M, et al. An examination of DSMIV depressive symptoms and risk of suicide completion in major depressive disorder. A psychological autopsy study. J Affect Disord 2007; 97: 203-9. (Pubitemid 44937433)
23. Tagariello P, Girardi P, Amore M. Depression and apathy in dementia: same syndrome or different constructs? A critical review. Arch Gerontol Geriatr 2009; 49: 246-9.
24. Agargun MY, Besiroglu L, Cilli AS, et al. Nightmares, suicide attempts, and melancholic features in patients with unipolar major depression. J Affect Disord 2007; 98: 267-70. (Pubitemid 46149061)
25. Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiat Scand 2008; 118: 106-15. (Pubitemid 351962155)
26. Zisok S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram int he STAR*D study. J Affect Disord 2009; 117: 63-73.
27. Mancini M, Gianni W, Rossi A, Amore M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opin Pharmacother 2009; 10: 847-60.
28. Musenga A, Amore M, Mandrioli R, Kenndler E, de Martino L, Raggi MA. Determination of duloxetine in human plasma by capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1126-32.
29. Mercolini L, Mandrioli L, Cazzolla R, Amore M, Raggi MA. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856: 81-7. (Pubitemid 47307438)
30. Mandrioli R, Mercolini L, Cesta R, Fanali S, Amore M, Raggi MA. Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856: 88-94. (Pubitemid 47307441)
31. Amore M, Jori MC; AMISERT Investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001; 16: 317-24. (Pubitemid 33030046)
32. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656-63.
33. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-18. (Pubitemid 30137678)
34. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001; 62: 358-61. (Pubitemid 32545558)
35. Almási J, Rihmer Z. Az antidepresszívumok áttekintése a TCA-któl a harmadik generációs szerekeig. Neuropsychopharmacol Hung 2004; 6: 185-94.
36. Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006; 21: 105-10. (Pubitemid 43740318)
37. Gartlehner G, Morgan LC, Thieda P, et al. Drug class review: Second generation antidepressants. Final Report Update 4 [Internet]. Portland (OR): Oregon Health & Science University; 2008. Available: http://www.ohsu.edu/ drug effectiveness/reports/final.cfm. Accessed January 1, 2010.
38. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149: 734-50.
39. San L, Arranz B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23: 396-402.
40. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-88. (Pubitemid 37429647)
41. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-56. (Pubitemid 44480844)
42. Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Human Psychopharmacol 2004; 19: 559-63. (Pubitemid 40028357)
43. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-60. (Pubitemid 40905587)
44. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and Ii depression. J Clin Psychopharmacol 2006; 26: 600-9.
45. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11: 999-1029.
46. Liebowitz MR, Salmán E, Mech A, et al. Ziprasidone monotherapy in bipolar II depression: an open trial. J Affect Disord 2009; 118: 205-8.
47. Bogart GT, Chavez B. Safety and efficacy of quetiapine in bipolar depression. Ann Pharmacother 2009; 43: 1848-56.
48. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012; 26: 435-60.
49. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition. Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-88.
50. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009; 11: 225-55.
51. Grunze HC. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression. Evid Based Ment Health 2010; 13: 88.
52. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarat monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70: 526-39.
53. Rihmer Z. A bipoláris betegség korszer- nozológiája. Neuropsychopharmacol Hung 2008; 10 (suppl 3): 5-12.
54. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-63.
55. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71: 150-62.
56. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71: 163-74.
57. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-88.
58. Suppes T, Kelly DI, Keck PE Jr, et al. Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network. Int Clin Psychopharmacol 2007; 22: 376-81. (Pubitemid 47530843)
59. Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry 2009; 9: 4.
60. Chang JS, Ha K. Management of bipolar depression. Indian J Psychol Med 2011; 33: 11-7.
61. Rihmer Z. [Antidepressive efficacy of quetiapine XR in unipolar major depression - the role of early onset of action and sleep-improving effect in decreasing suicide risk]. Neuropsychopharmacol Hung 2009; 11: 211-5.
62. Becker PM, Sattar M. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol 2009; 11: 349-57.
63. Todder D, Caliskan S, Baune BT. Night locomotor activity and quality of sleep in quetiapine-treated patients with depression. J Clin Psychopharmacol 2006; 26: 638-42. (Pubitemid 44772742)
64. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother 2009; 43: 707-13.
65. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012; 46: 718-22.
66. Maglione M, Maher AR, Hu J, et al. Off-label use of atypical antipsychotics: an update [Internet]. Rockville (MD): agency for healthcare research and quality (US); Report No.: 11-EHC087-EF, 2011.
67. Foral P, Dewan N, Malesker M. Insomnia: a therapeutic review for pharmacists. Consult Pharm 2011; 26: 332-41.
68. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-21.
69. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010; 127: 19-30.
70. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 2012 Jun 7 [Epub ahead of print].
71. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2012; 27: 27-39.
72. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128: 83-94.
73. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917-32.
74. Sagud M, Mihaljevic-Peles A, Mück-Seler D, Jakovljevic M, Pivac N. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology 2006; 187: 511-4. (Pubitemid 44200522)
75. Dorée JP, Des Rosiers J, Lew V, et al. Quetiapine augmentation of treatent-resistant depression: a comparison with lithium. Curr Med Res Opin 2007; 23: 333-41. (Pubitemid 46333382)
76. Dannlowski U, Baune BT, Böckermann I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positove effects on symptom reduction, psychopathology and remission rates. Human Psychopharmacol 2009; 23: 587-93.
77. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety 2012; 29: 574-86.
78. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: a 4-year follow-up naturalistic study. J Affect Disord 2008; 110: 135-41.
79. Soares CN, Frey BN, Haber E, Steiner M. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. J Clin Psychopharmacol 2010; 30: 612-5.
80. Innamorati M, Pompili M, Gonda X, et al. Psychometric properties of the Gotland Scale for Depression in Italian psychiatric inpatients and its utility in the prediction of suicide risk. J Affect Disord 2011; 132: 99-103.
81. Innamorati M, Pompili M, Serafini G, et al. Psychometric properties of the suicidal history self-rating screening scale. Arch Suicide Res 2011; 15: 87-92.